You are here

Stopping a Cholesterol-Lowering Drug Due to Aches and Pains May Be Dangerous in the Long Run

Patients who discontinue statins increase their risk for death, heart attack, or stroke

People who stopped taking statins after reporting a side effect were 13% more likely to die or have a heart attack or stroke over the next four years than people who kept taking the drugs, researchers found. Statins—which include the drugs atorvastatin (Lipitor, Pfizer); rosuvastatin (Crestor, AstraZeneca); and simvastatin (Zocor, Merck)—work by inhibiting the liver's ability to produce cholesterol while also helping the organ remove existing fats in the blood, according to the Centers for Disease Control and Prevention.

Statins are almost universally prescribed to people with heart disease. In addition, the U.S. Preventive Services Task Force recommends the drugs to people 40 to 75 years of age without a history of heart disease who have one or more risk factors and a 10-year risk of a heart attack or stroke of at least 10%.

Despite the overwhelming evidence in favor of statins, one-quarter to one-half of patients stop taking the drugs within six months to a year, Alexander Turchin, MD, of Brigham and Women's Hospital in Boston and colleagues wrote in the Annals of Internal Medicine.

To see whether people who continue taking statins—including those who switch to a different type or a lower dose—end up with better outcomes than people who stop taking the drugs, the researchers analyzed data from two Boston hospitals between 2000 and 2011. During that period, more than 200,000 adults were treated with statins. Nearly 45,000 of them reported a side effect they thought might be related to the medication, usually muscle or stomach aches.

From those 45,000 with possible side effects, the research team focused on 28,266 people. Most of them (19,989 individuals) kept taking statins anyway, with nearly half continuing to take the same drug.

Roughly four years after the side effects were reported, 3,677 patients had died or suffered a heart attack or stroke. Among those who continued to take their statins, 12.2% fell into that group, compared to 13.9% of those who stopped statins after a possible side effect.

Overall, the researchers found that people who stopped taking statins after a possible side effect were 13% more likely to die or have heart attack or stroke during the study period than people who kept taking their medicine.

The new findings expand on previous studies showing that people benefit when they continue to take their statins, said Robert Rosenson, MD, a professor of cardiology at the Icahn School of Medicine at Mount Sinai in New York City. Rosenson, who was not involved with the new study, said it's important for patients to tell their doctors about any possible side effects from statins because there may be other options.

"There are many different generic statins that can be tried," Rosenson told Reuters Health. Alternatively, he said, doctors may try giving a smaller dose of the drug.

Turchin told Reuters Health that doctors do sometimes take people off statins, depending on the severity of the side effects, the person's risk of cardiovascular disease, and other factors. "All of these different aspects should be taken into account in the discussion between patients and their physicians," he said.

In an editorial accompanying the new study, Steven Nissen, MD, of the Cleveland Clinic in Ohio, writes that some people may steer clear of statins due to misinformation published online or promoted in fad diets. "We must work together to educate the public and enlist media support, and we must take the time to explain to our patients that discontinuing statin treatment may be a life-threatening mistake," he writes.

Source: Reuters; July 24, 2017.

Recent Headlines

Company says it is offering a more affordable generic to the agent used to treat varicose veins
Company, FDA held a meeting to discuss trials in bunion, "tummy tuck" patients
New model uses piezoelectric material used in microphones and high-end speakers
Rozanolixizumab touted as possible alternative to standard therapy of corticosteroids, intravenous immunoglobulin
Intrauterine environment may have a 'programming effect' on fetal heart
Heart rate variability may pinpoint who will benefit
Researchers found that ECMO before transplant tripled chance of a long hospital stay